To combat antimicrobial resistance, invest in test-to-treat strategies
- CORRESPONDENCE
-
Rachel A. McKendry
-
University College London, London, UK.
-
-
Elliott Rogers
-
University College London, London, UK.
-
-
Mervyn Singer
-
University College London, London, UK.
-
-
Colin S. Brown
-
UK Health Security Agency, London, UK.
-
As the United Nations General Assembly’s high-level meeting on antimicrobial resistance (AMR) convenes in New York next week, we urge leaders to prioritize tackling a crucial blind spot: AMR test-to-treat data.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from $1.95
to $39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 633 , 525 (2024)
doi: https://doi.org/10.1038/d41586-024-03022-z
Competing Interests
M.S. receives funding for studies, advisory board or speaker work from the NIHR, Biomerieux, deePull, Gentian, Roche Diagnostics, Safeguard Biosystems, Volition. R.A.M. is an inventor on the UK patent application number 1814532.6 filed by University College London Business. C.S.B. does occasional ad hoc one-off market research advisory consultations – solely through market research companies (Sermo, Atheneum, M3). R.A.M. and C.S.B. are investigators for the EPSRC Digital Health Hub for AMR, for which Roche, Faculty, AWS, Arup and Microsoft are partners.
Related Articles
Subjects
Latest on: